JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, announced today that it has submitted a request to a European regulatory agency to begin pilot (Phase 1/2) clinical trials of BL-1040, an absorbable implant to treat cardiac tissue damaged as the result of an acute myocardial infarction (heart attack or MI). The submission comes following BioLineRx’s successful completion of pre-clinical studies of BL-1040.
